Joel Hirsh
Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Health Literacy | 8 | 2020 | 161 | 3.110 |
Why?
| Arthritis, Rheumatoid | 10 | 2020 | 1088 | 2.320 |
Why?
| Visual Analog Scale | 2 | 2019 | 28 | 1.070 |
Why?
| Patient Reported Outcome Measures | 2 | 2020 | 368 | 0.940 |
Why?
| Outpatient Clinics, Hospital | 2 | 2011 | 82 | 0.680 |
Why?
| Rheumatic Diseases | 1 | 2020 | 69 | 0.660 |
Why?
| Vulnerable Populations | 2 | 2019 | 157 | 0.620 |
Why?
| Patient Education as Topic | 3 | 2011 | 733 | 0.550 |
Why?
| Severity of Illness Index | 4 | 2013 | 2703 | 0.480 |
Why?
| Communication Barriers | 1 | 2016 | 98 | 0.480 |
Why?
| Rheumatology | 2 | 2020 | 106 | 0.460 |
Why?
| Health Knowledge, Attitudes, Practice | 3 | 2015 | 1272 | 0.450 |
Why?
| Trust | 1 | 2014 | 116 | 0.410 |
Why?
| Symptom Assessment | 1 | 2013 | 124 | 0.400 |
Why?
| Physician-Patient Relations | 2 | 2014 | 529 | 0.390 |
Why?
| Hospitals, Public | 1 | 2011 | 26 | 0.370 |
Why?
| Language | 1 | 2014 | 280 | 0.370 |
Why?
| Skin Diseases, Vascular | 1 | 2011 | 9 | 0.370 |
Why?
| Levamisole | 1 | 2011 | 19 | 0.370 |
Why?
| Drug Contamination | 1 | 2011 | 51 | 0.360 |
Why?
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2011 | 23 | 0.360 |
Why?
| Patient Participation | 1 | 2014 | 409 | 0.350 |
Why?
| Current Procedural Terminology | 1 | 2010 | 12 | 0.340 |
Why?
| Fees and Charges | 1 | 2010 | 10 | 0.340 |
Why?
| Online Systems | 1 | 2009 | 21 | 0.330 |
Why?
| Cocaine | 1 | 2011 | 148 | 0.320 |
Why?
| Fibromyalgia | 1 | 2009 | 55 | 0.320 |
Why?
| Decision Making | 1 | 2014 | 846 | 0.280 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2009 | 244 | 0.270 |
Why?
| Cross-Sectional Studies | 5 | 2019 | 5034 | 0.220 |
Why?
| Hospitals, Urban | 2 | 2012 | 129 | 0.190 |
Why?
| Internship and Residency | 1 | 2010 | 1043 | 0.170 |
Why?
| Middle Aged | 8 | 2019 | 30812 | 0.160 |
Why?
| Humans | 16 | 2020 | 128019 | 0.160 |
Why?
| Aged | 6 | 2019 | 21892 | 0.150 |
Why?
| Disability Evaluation | 1 | 2020 | 285 | 0.150 |
Why?
| Regression Analysis | 2 | 2011 | 978 | 0.150 |
Why?
| Male | 9 | 2019 | 62757 | 0.130 |
Why?
| Adult | 8 | 2019 | 35176 | 0.130 |
Why?
| Female | 10 | 2019 | 68016 | 0.130 |
Why?
| Culturally Competent Care | 1 | 2016 | 57 | 0.120 |
Why?
| Stomatognathic Diseases | 1 | 2014 | 4 | 0.110 |
Why?
| Patient Transfer | 2 | 2012 | 161 | 0.110 |
Why?
| Prosthesis-Related Infections | 1 | 2014 | 73 | 0.100 |
Why?
| Antibiotic Prophylaxis | 1 | 2014 | 101 | 0.100 |
Why?
| Refusal to Treat | 1 | 2012 | 17 | 0.100 |
Why?
| Young Adult | 3 | 2019 | 12281 | 0.090 |
Why?
| Arthroplasty, Replacement, Hip | 1 | 2014 | 135 | 0.090 |
Why?
| Linear Models | 1 | 2014 | 816 | 0.090 |
Why?
| Purpura | 1 | 2011 | 14 | 0.090 |
Why?
| Disease Progression | 1 | 2019 | 2598 | 0.090 |
Why?
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2011 | 34 | 0.090 |
Why?
| Antibodies, Antiphospholipid | 1 | 2011 | 23 | 0.090 |
Why?
| Advisory Committees | 1 | 2012 | 214 | 0.090 |
Why?
| Cyclophosphamide | 1 | 2011 | 227 | 0.090 |
Why?
| Surveys and Questionnaires | 3 | 2015 | 5353 | 0.090 |
Why?
| Prednisone | 1 | 2011 | 230 | 0.090 |
Why?
| Healthcare Disparities | 1 | 2016 | 579 | 0.080 |
Why?
| Arthroplasty, Replacement, Knee | 1 | 2014 | 300 | 0.080 |
Why?
| Self Care | 1 | 2011 | 368 | 0.070 |
Why?
| Reproducibility of Results | 1 | 2016 | 3009 | 0.070 |
Why?
| Comprehension | 1 | 2009 | 165 | 0.070 |
Why?
| Adolescent | 2 | 2019 | 20158 | 0.070 |
Why?
| Biopsy | 1 | 2011 | 1077 | 0.070 |
Why?
| Antirheumatic Agents | 1 | 2010 | 278 | 0.070 |
Why?
| Aged, 80 and over | 1 | 2019 | 7029 | 0.070 |
Why?
| Educational Status | 1 | 2009 | 470 | 0.070 |
Why?
| Urban Population | 1 | 2010 | 440 | 0.070 |
Why?
| Length of Stay | 1 | 2012 | 1114 | 0.070 |
Why?
| Skin | 1 | 2011 | 711 | 0.060 |
Why?
| Patient Discharge | 1 | 2012 | 850 | 0.060 |
Why?
| Follow-Up Studies | 2 | 2014 | 4853 | 0.060 |
Why?
| Pilot Projects | 1 | 2009 | 1559 | 0.060 |
Why?
| Curriculum | 1 | 2010 | 909 | 0.050 |
Why?
| United States | 3 | 2014 | 13785 | 0.050 |
Why?
| Organizational Case Studies | 2 | 2012 | 74 | 0.050 |
Why?
| Medically Uninsured | 2 | 2012 | 127 | 0.050 |
Why?
| Emergency Service, Hospital | 1 | 2012 | 1896 | 0.050 |
Why?
| Treatment Outcome | 2 | 2014 | 10110 | 0.040 |
Why?
| Prospective Studies | 1 | 2011 | 7035 | 0.040 |
Why?
| Osteoarthritis, Hip | 1 | 2014 | 43 | 0.030 |
Why?
| Uncompensated Care | 1 | 2012 | 19 | 0.030 |
Why?
| Mental Competency | 1 | 2012 | 27 | 0.020 |
Why?
| Hospital Charges | 1 | 2012 | 41 | 0.020 |
Why?
| Colorado | 2 | 2012 | 4369 | 0.020 |
Why?
| Unnecessary Procedures | 1 | 2012 | 48 | 0.020 |
Why?
| Preoperative Care | 1 | 2014 | 335 | 0.020 |
Why?
| Bacteremia | 1 | 2014 | 192 | 0.020 |
Why?
| Travel | 1 | 2012 | 121 | 0.020 |
Why?
| Osteoarthritis, Knee | 1 | 2014 | 239 | 0.020 |
Why?
| Continuity of Patient Care | 1 | 2012 | 275 | 0.020 |
Why?
| Case-Control Studies | 1 | 2014 | 3324 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2014 | 1482 | 0.020 |
Why?
| Risk Assessment | 1 | 2014 | 3223 | 0.010 |
Why?
| Mental Disorders | 1 | 2012 | 1005 | 0.010 |
Why?
|
|
Hirsh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|